Mr. Hermes Chan reports

MEDMIRA RECEIVES HEALTH CANADA APPROVAL FOR ITS REVEAL G4 RAPID HIV-1/2 TEST FOR POINT-OF-CARE USE

Medmira Inc. has received the approval from Health Canada for its RevealRapid G4 HIV-1/2 test for point-of-care use. The Reveal HIV rapid test has achieved a sensitivity of 99.64 per cent and a specificity of 99.71 per cent, and it is highly suitable for health care professionals who require a fast, reliable and high-quality result to be used in any health care setting.

The Reveal HIV test enables an immediate result to accurately detect HIV-1/2 antibodies with only a small sample using a finger prick. The less then one-minute easy steps to complete the test (after sample collection) allow an operator to achieve an immediate result that does not fade away. This together with the no special storage requirement makes the Reveal HIV test a highly suitable tool for any health care setting.

The product is based on Medmira's unique and patented rapid vertical flow technology with an inbuild reagent and procedural control line, which enables users to be sure the test is performed correctly. This distinctive feature provides the comfort and security that a test has been correctly completed. An essential part for any rapid testing, especially for life-changing diagnoses such as HIV.

"Our Reveal HIV test is one of the fastest and most reliable solutions for HIV detection. As the rates of HIV infections continue to rise in Canada, health care providers need diagnostics that are not only accurate but also simple, cost-effective and accessible in any setting. Whether in underserved remote areas or urban centres facing overburdened health care systems, our test is designed to provide immediate and actionable results," said Hermes Chan, chief executive officer of Medmira. "Together with our partners, such as Reach Nexus, we are committed to rapidly deploying our innovative solutions and supporting Canada's public health efforts to modernize and expand HIV screening."

The latest data from the Public Health Agency of Canada show that new HIV diagnoses soared more than 35 per cent from 2022 to 2023, with rates in Manitoba rising by more than 40 per cent. In Saskatchewan, the rate of HIV was 19.4 per 100,000 people, more than three times the national rate.

This approval comes after the received approval of Medmira's Multiplo TP/HIV rapid test on Dec. 24, 2024. The company's aim is to provide the Canadian market with a suite of alternatives as certain health care settings and programs or professionals aim for a specific disease. Hence, the company offers its Multiplo TP/HIV combination test or its Reveal single marker tests such as Reveal HIV test. Medmira anticipates the approval of the Reveal TP test in the coming weeks.

About Medmira Inc.

Medmira is a leading developer and manufacturer of rapid vertical flow diagnostics. The company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, syphilis, hepatitis and SARS-CoV-2 in just three easy steps. The company's tests are sold globally under the Reveal, RevealCOVID-19, Multiplo and Miriad brands. Based on its patented rapid vertical flow technology, Medmira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. Medmira's corporate offices and manufacturing facilities are located in Halifax, N.S., Canada.

We seek Safe Harbor.